Germany
· Delayed Price · Currency is EUR Co-Diagnostics Statistics
Total Valuation
Co-Diagnostics has a market cap or net worth of EUR 5.01 million. The enterprise value is -4.08 million.
| Market Cap | 5.01M |
| Enterprise Value | -4.08M |
Important Dates
The last earnings date was Tuesday, March 31, 2026.
| Earnings Date | Mar 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 2.03M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +31.55% |
| Shares Change (QoQ) | +49.14% |
| Owned by Insiders (%) | 2.86% |
| Owned by Institutions (%) | 6.90% |
| Float | 3.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.46 |
| PB Ratio | 0.29 |
| P/TBV Ratio | 0.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.10 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.16 |
Financial Position
The company has a current ratio of 3.87, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.87 |
| Quick Ratio | 3.42 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.04 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -125.89% and return on invested capital (ROIC) is -157.06%.
| Return on Equity (ROE) | -125.89% |
| Return on Assets (ROA) | -44.28% |
| Return on Invested Capital (ROIC) | -157.06% |
| Return on Capital Employed (ROCE) | -147.54% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 4,610 |
| Profits Per Employee | -347,315 |
| Employee Count | 115 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.22 |
Taxes
| Income Tax | -1.38M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 165 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.04 |
Income Statement
In the last 12 months, Co-Diagnostics had revenue of EUR 530,174 and -39.94 million in losses. Loss per share was -30.03.
| Revenue | 530,174 |
| Gross Profit | 340,775 |
| Operating Income | -26.64M |
| Pretax Income | -41.32M |
| Net Income | -39.94M |
| EBITDA | -25.70M |
| EBIT | -26.64M |
| Loss Per Share | -30.03 |
Balance Sheet
The company has 10.12 million in cash and 1.05 million in debt, giving a net cash position of 9.07 million.
| Cash & Cash Equivalents | 10.12M |
| Total Debt | 1.05M |
| Net Cash | 9.07M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 17.57M |
| Book Value Per Share | 8.39 |
| Working Capital | 8.65M |
Cash Flow
In the last 12 months, operating cash flow was -24.82 million and capital expenditures -596,230, giving a free cash flow of -25.41 million.
| Operating Cash Flow | -24.82M |
| Capital Expenditures | -596,230 |
| Depreciation & Amortization | 944,968 |
| Net Borrowing | n/a |
| Free Cash Flow | -25.41M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 64.28% |
| Operating Margin | -5,025.53% |
| Pretax Margin | -7,793.21% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Co-Diagnostics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -31.55% |
| Shareholder Yield | -31.55% |
| Earnings Yield | -796.48% |
| FCF Yield | -506.75% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Co-Diagnostics has an Altman Z-Score of -5.9 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.9 |
| Piotroski F-Score | 1 |